Molecular Analysis of Antilipemic Effects of FR218944, a Novel Vasopressin V1a Receptor Antagonist, in Genetically Diabetic db/db Mice in Comparison with Pioglitazone and Fenofibrate

Drug Development Research

Volumn 60, Issue 4, 2003, Pages 241-251

  Morita, Masahiko ^a   Ohkubo Suzuki, Akiko ^a   Takahashi, Tokiko ^a   Nagashima, Akira ^a   Sawada, Yuki ^a   Ohkawa, Takehiko ^a   Nishimura, Shintaro ^a   Kita, Yasuhiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

oxidation; Fenofibrate; FR218944; Pioglitazone; Triglyceride; V1aR

Indexed keywords

2 METHOXY N (2 METHYL 1H BENZIMIDAZOL 4 YL) 4 (2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YLCARBONYL)BENZAMIDE METHANESULFONATE; ACYL COENZYME A OXIDASE; FENOFIBRATE; FR 218944; GLUCOSE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILIPEMIC ACTIVITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE CONTROL; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; MALE; MOUSE; NONHUMAN; REVIEW; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 0345306704     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10323     Document Type: Review

References (25)

1. Assimacopoulos-Jeannet F, Denton RM, Jeanrenaud B. 1981. Stimulation of hepatic lipogenesis and acetyl-coenzyme A carboxylase by vasopressin. Biochem J 198:485-490.
2. Cottet-Maire F, Avdonin PV, Roulet E, Buetler TM, Mermod N, Ruegg UT. 2001. Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment. Br J Pharmacol 132:909-917.
3. Eugenin EA, Gonzalez H, Saez CG, Saez JC. Gap junctional 1998. Communication coordinates vasopressin-induced glycogenolysis in rat hepatocytes. Am J Physiol 274:G1109-G1116.
4. Guo Q, Wang PR, Milot DP, Ippolito MC, Hernandez M, Burton CA, Wright SD, Chao Y. 2001. Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim Biophys Acta 1533:220-232.
5. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferre P. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399.
6. Ikeda S, Miyazaki H, Nakatani T, Kai Y, Kamei Y, Miura S, Tsuboyama-Kasaoka N, Ezaki O. 2002. Up-regulation of SREBP-1c and lipogenic genes in skeletal muscles after exercise training. Biochem Biophys Res Commun 296:395-400.
7. Jackson EK. 1996. Vasopressin and other agents affecting the renal conservation of water. In: Hardmann JG, Limbird LE, editors. The pharmacological basis of therapeutics, ninth edition. New York: McGraw Hill. p 715-731.
8. Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH. 1986. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol 30:171-177.
9. Jard S, Lombard C, Marie J, Devilliers G. 1987. Vasopressin receptors from cultured mesangial cells resemble V1a type. Am J Physiol 253:F41-F49.
10. Kim JB, Spiegelman BM. 1996. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 10:1096-1107.
11. Kurihara I, Saito T, Obara K, Shoji Y, Hirai M, Soma J, Sato H, Imai Y, Abe K. 1996. Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron 73:629-636.
12. Lavoie L, van de Werve G. 1991. Hormone-stimulated glucose production from glycogen in hepatocytes from streptozotocin diabetic rats. Metabolism 40:1031-1036.
13. Marchingo AJ, Abrahams JM, Woodcock EA, Smith AI, Mendelsohn FA, Johnston CI. 1988. Properties of [3H]1-desamino-8-D-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney. Endocrinology 122:1328-1336.
14. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. 2002. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62:1463-1480.
15. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ. 1992. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356:523-526.
16. Morita M, Kita Y, Morikawa N, Iwami M, Notsu Y. 2001. Expression of arginine vasopressin and vasopressin V1a receptor mRNA in diabetic (db/db) mice. Exp Clin Endocrinol Diabetes 109: 261-266.
17. Ostrowski NL, Lolait SJ, Young WS 3rd. 1994. Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinology 135:1511-1528.
18. Phillips PA, Risvanis J, Hutchins AM, Burrell LM, MacGregor D, Gundlach AL, Johnston CI. 1995. Down-regulation of vasopressin V1a receptor mRNA in diabetes mellitus in the rat. Clin Sci (Lond) 88:671-674.
19. Rossi R, Scharrer E. 1993. Mechanisms of the effects of vasopressin on plasma levels of free fatty acids and triglycerides in pygmy goats. Comp Biochem Physiol Comp Physiol 104: 287-290.
20. Stumvoll M, Haring HU. 2002. Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217-224.
21. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. 2002. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277:18919-18927.
22. Surapureddi S, Yu S, Bu H, Hashimoto T, Yeldandi AV, Kashireddy P, Cherkaoui-Malki M, Qi C, Zhu YJ, Rao MS, Reddy JK. 2002. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci USA 99:11836-11841.
23. Suzuki A, Yasuno T, Kojo H, Hirosumi J, Mutoh S, Notsu Y. 2000. Alteration in expression profiles of a series of diabetes-related genes in db/ db mice following treatment with thiazolidinediones. Jpn J Pharmacol 84:113-123.
24. Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, Terauchi Y, Matsui J, Akanuma Y, Kimura S, Tanaka J, Abe M, Ohsumi J, Nagai R, Kadowaki T. 2001. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J Biol Chem 276:38337-38340.
25. Trinder D, Phillips PA, Stephenson JM, Risvanis J, Aminian A, Adam W, Cooper M, Johnston CI. 1994. Vasopressin V1 and V2 receptors in diabetes mellitus. Am J Physiol 266:E217-E223.